AstraZeneca PLC (NASDAQ:AZN) Receives $86.00 Consensus Target Price from Analysts

Shares of AstraZeneca PLC (NASDAQ:AZN) have been given a consensus rating of “Moderate Buy” by the six analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $86.00.

AZN has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Jefferies Financial Group initiated coverage on AstraZeneca in a report on Monday. They issued a “buy” rating on the stock. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Finally, Berenberg Bank set a $97.00 price target on AstraZeneca in a research note on Wednesday, July 9th.

AstraZeneca Stock Down 0.5%

NASDAQ:AZN opened at $82.23 on Monday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The company has a market capitalization of $255.03 billion, a PE ratio of 30.91, a P/E/G ratio of 1.52 and a beta of 0.36. The firm’s 50-day moving average price is $81.06 and its 200-day moving average price is $74.82. AstraZeneca has a 1-year low of $61.24 and a 1-year high of $86.57.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. The business had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The company’s revenue was up 16.1% on a year-over-year basis. During the same period last year, the firm posted $1.24 EPS. On average, equities analysts predict that AstraZeneca will post 4.51 EPS for the current fiscal year.

Institutional Investors Weigh In On AstraZeneca

Large investors have recently modified their holdings of the stock. NewSquare Capital LLC increased its position in shares of AstraZeneca by 149.3% during the 2nd quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after purchasing an additional 218 shares during the period. Larson Financial Group LLC increased its position in shares of AstraZeneca by 297.9% in the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock valued at $28,000 after buying an additional 289 shares in the last quarter. Richardson Financial Services Inc. increased its position in shares of AstraZeneca by 59.8% in the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after buying an additional 149 shares in the last quarter. Costello Asset Management INC bought a new stake in shares of AstraZeneca in the 1st quarter valued at $29,000. Finally, FSA Wealth Management LLC boosted its stake in AstraZeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock worth $33,000 after purchasing an additional 376 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.